A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
Not yet recruitingCTIS2025-523087-20-00
Avidity Biosciences Inc.Duchenne muscular dystrophy
Target: 26Updated: 2026-05-20